Medicines Pricing and Reimbursement: Demonstrating Value and Sharing Risk in the EU and United States

In both the European Union and United States, commissioners, regulators, and payers are making increasing evidential demands to show value in relation to the pricing and reimbursement of innovative medicines. Although the mechanisms differ, these demands stem from the same driver—the perceived need to control healthcare product budgets. Join our Washington, DC, and London lawyers and pricing and reimbursement experts for a one-hour webinar to discuss the issues and challenges arising from the growing need in both countries for producers to demonstrate value and share risk.

Topics will include:

• EU-level controls and the consequences of member state autonomy
• Pricing strategies for specialty products and rare diseases in the EU and United States
• Health technology assessment and outcomes research for demonstrating and promoting value
• Risk-sharing agreements, patient access schemes, and controls on drug spend
• G2N mandatory discounts and rebates